Summit Global Investments Has $12.73 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Summit Global Investments trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 27.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,081 shares of the biotechnology company’s stock after selling 13,918 shares during the period. United Therapeutics accounts for approximately 0.8% of Summit Global Investments’ holdings, making the stock its 25th largest position. Summit Global Investments owned about 0.08% of United Therapeutics worth $12,731,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the fourth quarter worth $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $33,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in United Therapeutics in the 4th quarter worth approximately $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $919,164.36. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several analyst reports. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Down 0.2 %

Shares of UTHR opened at $312.99 on Friday. The stock’s 50-day moving average price is $345.10 and its 200 day moving average price is $356.99. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The firm has a market capitalization of $14.06 billion, a price-to-earnings ratio of 13.75, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the company posted $4.36 earnings per share. Equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.